Investors wanted more good news than they got in the specialty-drug maker's fourth-quarter update.
News & Analysis: AcelRx Pharmaceuticals
These three small-cap stocks have outstanding growth potential.
AcelRx and Novavax are two penny biotech stocks worth checking out in this latest market downturn.
When you invest in a business, you should expect to stay with it for the long haul.
After earning FDA marketing approval for a controversial new drug, the company is raising cash through a share offering.
Nothing to worry about after the biotech received a much-needed FDA approval last week.
With new drug applications under review at the moment, these 3 biotech stocks could surge in the weeks ahead.
A positive recommendation from an FDA advisory committee generates excitement among investors about this small biotech.
Good news from the FDA lit a fire beneath this biotech stock. Can the momentum continue?
Traders toy with the share price ahead of an advisory committee meeting.